2/24
07:00 am
ocul
Ocular Therapeutix™ to Participate in March Investor Conferences
Medium
Report
Ocular Therapeutix™ to Participate in March Investor Conferences
2/23
07:00 am
ocul
Ocular Therapeutix™ to Present Detailed SOL-1 Data at the 49th Macula Society Annual Meeting and Host Investor Webcast to Discuss Presentations
Medium
Report
Ocular Therapeutix™ to Present Detailed SOL-1 Data at the 49th Macula Society Annual Meeting and Host Investor Webcast to Discuss Presentations
2/22
07:44 pm
ocul
Reassessing Ocular Therapeutix (OCUL) After Sharp Pullback And Conflicting Valuation Signals [Yahoo! Finance]
High
Report
Reassessing Ocular Therapeutix (OCUL) After Sharp Pullback And Conflicting Valuation Signals [Yahoo! Finance]
2/20
08:03 am
ocul
Ocular Therapeutix (NASDAQ:OCUL) had its price target lowered by analysts at Needham & Company LLC from $20.00 to $18.00. They now have a "buy" rating on the stock.
High
Report
Ocular Therapeutix (NASDAQ:OCUL) had its price target lowered by analysts at Needham & Company LLC from $20.00 to $18.00. They now have a "buy" rating on the stock.
2/18
01:04 pm
ocul
Ocular Therapeutix Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses
Low
Report
Ocular Therapeutix Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses
2/18
08:13 am
ocul
Ocular Therapeutix (NASDAQ:OCUL) had its "buy" rating reaffirmed by analysts at Chardan Capital. They now have a $21.00 price target on the stock.
Low
Report
Ocular Therapeutix (NASDAQ:OCUL) had its "buy" rating reaffirmed by analysts at Chardan Capital. They now have a $21.00 price target on the stock.
2/17
04:16 pm
ocul
Ocular Therapeutix, Inc. (OCUL) Discusses Positive Top Line Results From SOL-1 Phase 3 Trial of AXPAXLI in Wet AMD Transcript [Seeking Alpha]
Low
Report
Ocular Therapeutix, Inc. (OCUL) Discusses Positive Top Line Results From SOL-1 Phase 3 Trial of AXPAXLI in Wet AMD Transcript [Seeking Alpha]
2/12
09:56 am
ocul
Ocular Therapeutix: Considering Their Phase 3 'Superiority' Trial's Prospect [Seeking Alpha]
Low
Report
Ocular Therapeutix: Considering Their Phase 3 'Superiority' Trial's Prospect [Seeking Alpha]
2/6
04:01 pm
ocul
Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2/5
06:08 pm
ocul
Ocular Therapeutix (NASDAQ:OCUL) Misses Q4 CY2025 Revenue Estimates [Yahoo! Finance]
Low
Report
Ocular Therapeutix (NASDAQ:OCUL) Misses Q4 CY2025 Revenue Estimates [Yahoo! Finance]
2/5
01:28 pm
ocul
Ocular Therapeutix's Recent Stock Weakness Presents Buying Opportunity, RBC Says [Yahoo! Finance]
Medium
Report
Ocular Therapeutix's Recent Stock Weakness Presents Buying Opportunity, RBC Says [Yahoo! Finance]
2/5
10:58 am
ocul
Ocular Therapeutix (NASDAQ:OCUL) had its "outperform" rating reaffirmed by analysts at Royal Bank Of Canada.
Medium
Report
Ocular Therapeutix (NASDAQ:OCUL) had its "outperform" rating reaffirmed by analysts at Royal Bank Of Canada.
2/5
07:18 am
ocul
Ocular Therapeutix: Q4 Earnings Snapshot [Yahoo! Finance]
Low
Report
Ocular Therapeutix: Q4 Earnings Snapshot [Yahoo! Finance]
2/5
07:17 am
ocul
Ocular Therapeutix GAAP EPS of -$0.29, revenue of $13.25M [Seeking Alpha]
Low
Report
Ocular Therapeutix GAAP EPS of -$0.29, revenue of $13.25M [Seeking Alpha]
2/5
07:00 am
ocul
Ocular Therapeutix™ Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights
Medium
Report
Ocular Therapeutix™ Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights
2/4
07:46 am
ocul
Ocular Therapeutix: Why SOL-1 Trial Outcome Is Likely Positive [Seeking Alpha]
Low
Report
Ocular Therapeutix: Why SOL-1 Trial Outcome Is Likely Positive [Seeking Alpha]
1/23
04:01 pm
ocul
Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Medium
Report
Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
1/21
07:00 am
ocul
Ocular Therapeutix™ Appoints David W. Robinson as Global Chief Commercial Officer
Low
Report
Ocular Therapeutix™ Appoints David W. Robinson as Global Chief Commercial Officer
1/15
06:42 am
ocul
3 Reasons OCUL is Risky and 1 Stock to Buy Instead [Yahoo! Finance]
High
Report
3 Reasons OCUL is Risky and 1 Stock to Buy Instead [Yahoo! Finance]
1/7
05:38 pm
ocul
Is It Too Late To Consider Ocular Therapeutix (OCUL) After Recent Share Price Volatility? [Yahoo! Finance]
Low
Report
Is It Too Late To Consider Ocular Therapeutix (OCUL) After Recent Share Price Volatility? [Yahoo! Finance]
1/2
06:15 pm
ocul
Ocular Therapeutix (NASDAQ:OCUL) Surprises With Q3 CY2025 Sales [Yahoo! Finance]
Low
Report
Ocular Therapeutix (NASDAQ:OCUL) Surprises With Q3 CY2025 Sales [Yahoo! Finance]
12/31
11:30 am
ocul
BofA Bullish on Ocular Therapeutix (OCUL) as AXPAXLI Targets Superiority Label and Faster Regulatory Path in Wet AMD [Yahoo! Finance]
Low
Report
BofA Bullish on Ocular Therapeutix (OCUL) as AXPAXLI Targets Superiority Label and Faster Regulatory Path in Wet AMD [Yahoo! Finance]
12/9
08:19 am
ocul
Ocular Therapeutix (NASDAQ:OCUL) had its "buy" rating reaffirmed by analysts at Chardan Capital. They now have a $21.00 price target on the stock.
Low
Report
Ocular Therapeutix (NASDAQ:OCUL) had its "buy" rating reaffirmed by analysts at Chardan Capital. They now have a $21.00 price target on the stock.
12/8
11:41 am
ocul
Ocular Therapeutix (NASDAQ:OCUL) had its "buy" rating reaffirmed by analysts at Needham & Company LLC. They now have a $20.00 price target on the stock.
Low
Report
Ocular Therapeutix (NASDAQ:OCUL) had its "buy" rating reaffirmed by analysts at Needham & Company LLC. They now have a $20.00 price target on the stock.
12/8
07:03 am
ocul
Ocular Therapeutix (NASDAQ:OCUL) had its "buy" rating reaffirmed by analysts at HC Wainwright.
High
Report
Ocular Therapeutix (NASDAQ:OCUL) had its "buy" rating reaffirmed by analysts at HC Wainwright.